View Document Preview and Link Open Document File Size: 42,75 KB Share Result on Facebook
City Beltsville / Reference / Monmouth Junction / / Company Sciecure Pharma / PhD President Sciecure Pharma Inc. / BCPS / PharmD / PhD Sciecure Pharma / / Event FDA Phase / Product Issues / Product Recall / / / IndustryTerm treatment of insomnia / healthcare professionals / drug product / prescription drug product / / MedicalCondition acute and chronic insomnia / insomnia / several other disorders / headache / next-day psychomotor impairment / benzodiazepine withdrawal syndrome / pulmonary insufficiency / fatigue / daytime drowsiness / hypersensitivity / dizziness / chronic insomnia / depression / suspected sleep apnea / / MedicalTreatment Pharmacotherapy / / Organization Food and Drug Administration / U.S. Food and Drug Administration / DOSAGE AND ADMINISTRATION / office of Prescription Drug Promotion / Center for Drug Evaluation and Research / DEPARTMENT OF HEALTH / / Person MATHILDA K FIENKENG / Silver Spring / Mathilda Fienkeng / Wang / Melinda McLawhorn / / Position Team Leader / Regulatory Review Officer / / Product syndrome / DORAL / triazolam / Doral tablets / DORAL® (quazepam) Tablets / activities / / ProvinceOrState New Jersey / Maryland / / Technology pharmacokinetics / pharmacodynamics / / SocialTag 
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993